Los Angeles-based Kite Pharma, a biopharmaceuticals firm focused on cancer treatments, announced this morning that it has appointed Adrian Bot, M.D., Ph.D., as its Chief Scientific Officer. Dr. Bot joins the company from MannKind Corp., where he was Vice PResident of Research. He also has served at Allecure Corp. and Alliance Pharmaceutical Corp, and was a post-graduate at Scripps Research Institute. Kite Pharma recently raised $15M in a first round of venture funding from TPG Capital.